Open Label Trial for Post-Menopausal Women With Newly Diagnosed Operable Breast Cancer

Exclusion Criteria

• •Current, recent (within 4 weeks of the first infusion of this study), or planned participation in an experimental drug study other than this sponsor-investigator Bevacizumab cancer study.
• •Uncontrolled high blood pressure (150/100 mmHg)
• •Unstable angina
• •New York Heart Association (NYHA) Grade II or greater congestive heart failure see Appendix G)
• •History of myocardial infarction within 6 months
• •History of stroke within 6 months
• •Clinically significant peripheral vascular disease
• •History of a bleeding disorder
• •Presence of central nervous system or brain metastases
• •Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 0, anticipation of need for major surgical procedure during the course of the study
• •Minor surgical procedures, fine needle aspirations or core biopsies within 7 days prior to Day 0
• •Pregnant (positive pregnancy test) or lactating
• •Urine protein: creatinine ratio 1.0 at screening. Patients demonstrating \> 1 gr of protein in 24 hr urine collection within 4 weeks prior to study entry will not participate in the trial.
• •History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to Day 0
• •Serious, non-healing wound, ulcer, or bone fracture
• •Unwilling or unable to comply with the protocol for the duration of the study.
• •Psychiatric illness/social situations that would limit compliance with study requirements.
• •History of another malignancy within the last five years except cured basal cell carcinoma of skin and carcinoma in-situ of uterine cervix.
• •Patients with metastatic disease.